Alfuzosin Hydrochloride
Product Images NDC 63629-7907

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 63629-7907). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 01

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 02

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 03

This appears to be a graph or table showing the mean change in some measure (not specified) over the course of 28, 56, and 84 days of treatment, comparing a placebo group (N=167) to a group taking a medication called Altuzosin hydrochloride extended-release tablets (N=170). The asterisks next to the "p<0.001" suggest that the difference between the two groups is statistically significant. However, without more information about what is actually being measured, it is difficult to provide a more specific description.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 04

The text describes a study, which involved two groups of people. One group (N=152) received placebo, while the other group (N=137) received Alfuzosin hydrochloride extended-release tablets. The study lasted for 28, 56, and 84 days of treatment. The asterisks indicate that the results were statistically significant (p<0.01). The text does not provide further details on the study or its findings.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 05

This is a chart showing the mean change over days of treatment for a placebo group and a group treated with Altuzosin hydrochloride extended-release tablets. The chart indicates significant improvement in the group treated with Altuzosin hydrochloride.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 06

The text describes the mean change in mL/s over a period of 56 to 84 days of treatment using a placebo and alfuzosin hydrochloride extended-release tablets, with a significant difference between the two treatments.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 07

This is a graph showing the mean change in mL/s in patients receiving placebo (N=147) and alfuzosin hydrochloride extended-release tablets (N=136) over a period of 84 days. The graph indicates that alfuzosin hydrochloride extended-release tablets were more effective in improving mL/s as compared to placebo. The asterisk indicates statistical significance with p<0.05.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 08

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 09

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 10

FDA Label Image

Label Image (Lbl636297907)

This medication is called Alfuzosin Hydrochloride, which comes in the form of white round tablets marked with U;155. Each tablet is 10mg and may cause dizziness. The tablets are packaged by Bryant Ranch Prepack Burbank and should be stored at room temperature between 20°-25°C (68°-77°F). The expiration date for this batch of tablets is not mentioned. This medicine is a generic version of Uroxatral 10mg tablet and is sold under the brand Liberprost. It is recommended to keep all medications out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.